Buy
Average UserBuy
Average AnalystBullish
Stock Target AdvisorUSD 110.22
-0.71 (-0.64)%
USD 10.41B
0.82M
USD 119.77(+8.67%)
Buy
Average UserBuy
Average AnalystBullish
Stock Target AdvisorUSD 10.41B
USD 110.22
Based on the Neurocrine Biosciences Inc stock forecasts from 15 analysts, the average analyst target price for Neurocrine Biosciences Inc is USD 119.77 over the next 12 months. Neurocrine Biosciences Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Neurocrine Biosciences Inc is Bullish , which is based on 11 positive signals and 4 negative signals. At the last closing, Neurocrine Biosciences Inc’s stock price was USD 110.22. Neurocrine Biosciences Inc’s stock price has changed by +1.31% over the past week, -7.72% over the past month and +39.13% over the last year.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical ...Read More
12780 El Camino Real, San Diego, CA, United States, 92130
1,150
December
USD
USA
0.52
USD 129.29
3.35
USD 75.25
2,594,066
USD 104.62
2,251,549
USD 117.07
1.00%
3.10%
96.92%
N/A
Security | Capital Gain | Dividend Return | Total Return |
---|
Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
---|---|---|---|---|---|
|
PPD Inc | 0.00 (0.00%) | USD16.61B | 47.04 | 21.58 |
|
Viatris Inc | +0.10 (+0.82%) | USD14.42B | 18.02 | 6.97 |
|
Mylan N.V | 0.00 (0.00%) | USD8.59B | 30.73 | 11.86 |
|
Tilray, Inc | 0.00 (0.00%) | USD6.86B | 60.60 | 454.68 |
|
Momenta Pharmaceuticals, Inc | 0.00 (0.00%) | USD6.24B | N/A | N/A |
|
Alkermes Plc | +0.05 (+0.17%) | USD4.73B | N/A | -72.85 |
|
Intracellular Th | -0.10 (-0.21%) | USD4.45B | N/A | -14.58 |
|
Lantheus Holdings Inc | +1.14 (+1.98%) | USD3.86B | 36.91 | 16.96 |
|
Evotec SE ADR | +0.10 (+1.03%) | USD3.66B | 508.00 | -19.09 |
|
HUTCHMED DRC | +0.73 (+4.05%) | USD3.64B | 17.69 | -6.38 |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
|
Invesco Dynamic Biotechno.. | 4.30 % | 0.57 % | +0.39 (+0.58%) | USD0.26B |
|
Vanguard S&P Mid-Cap 400 .. | 1.10 % | 0.08 % | +2.57 (+1.42%) | USD0.75B |
|
Vanguard Small-Cap Growth.. | 0.63 % | 0.07 % | +4.94 (+2.21%) | USD13.26B |
|
SPDR® S&P MIDCAP 400 ETF.. | 0.56 % | 0.22 % | +7.75 (+1.60%) | USD19.78B |
|
SSgA SPDR ETFs Europe I P.. | 0.56 % | 0.30 % | +1.05 (+1.33%) | USD1.35B |
|
Vanguard S&P Mid-Cap 400 .. | 0.55 % | 0.08 % | +2.72 (+1.52%) | USD1.54B |
Heading 1 | Heading 2 | Heading 3 | Heading 4 | Heading 5 |
---|---|---|---|---|
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.